Alnylam said the green light makes Amvuttra the first and only RNAi therapeutic approved in Europe for the treatment of the cardiomyopathy manifestations of ATTR amyloidosis and the polyneuropathy ...

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNA interference (RNAi) therapeutics company, today announced that the European Commission (EC) has granted approval for the treatment of wild ...

As multiple companies vie to expand on Alnylam’s success in commercializing RNAi therapeutics, the pioneering company has set ...

Biopharma financings totaled $21.38 billion through May 2025, down sharply from $62.57 billion during the same period in 2024, but roughly in line with levels seen in 2023 and 2022. Biopharma ...

The standard of care for managing patients with type 2 diabetes and CKD -- in addition to a healthy lifestyle -- has always ...

Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Alnylam Pharmaceuticals Inc. won’t get another chance at its patent infringement suit against Moderna Inc. over its mRNA Covid-19 vaccine, a federal appeals court ruled Wednesday.

In a precedential decision issued June 4, 2025, the U.S. Court of Appeals for the Federal Circuit (CAFC) affirmed a district court's finding of noninfringement in favor of Moderna, Inc. in its ongoing ...

Moderna convinced a U.S. appeals court on Wednesday to uphold a ruling that undercut patent infringement claims by biotech ...

Detailed price information for Rocket Pharmaceuticals Inc (RCKT-Q) from The Globe and Mail including charting and trades.

Moderna Inc. once again emerged the winner in a court skirmish over claims that its COVID-19 vaccine infringed two Alnylam Pharmaceuticals Inc. patents. The U.S. Court of Appeals for the Federal ...

H.C. Wainwright’s Patrick Trucchio reiterated his Buy rating on Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) and raised his ...